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LGE and the Risk of
Sudden Death in HCM
We read with interest the recent paper by Green et al. (1) and wish
to congratulate them for this timely article. The investigators
performed a meta-analysis assessing the value of late gadolinium
enhancement (LGE) on cardiac magnetic resonance (CMR) for
predicting clinical outcomes in hypertrophic cardiomyopathy. Al-
though the investigators found a significant association between
LGE and cardiac death, heart failure death, and all-cause mortality,
this was not statistically significant for sudden cardiac death (SCD)
or aborted SCD. In this regard, we would like to point to 3
important issues. First, in the study by O’Hanlon et al. (2), the
authors report SCD/aborted SCD events as 3 and 1 in the LGE
and LGE groups, respectively. However, if one were to review
this paper carefully, O’Hanlon et al. (2) report sustained ventricular
tachycardia (VT)/ventricular fibrillation (VF), SCD, and appropri-
ate implantable cardioverter-defibrillator (ICD) discharges sepa-
rately. The composite arrhythmic event rates were in fact 10 and 2
in the LGE and LGE groups, respectively. We believe that
Synthes
Author Year Sample Index Referen
  Size Group Group
O’Hanlon 2010 217 10 (136) 2 (81
Bruder 2010 220 10 (148) 1 (72
Rubinstein 2010 424 8 (239) 0 (185
Maron MS 2008 202 4 (111) 3 (91
Synthesis  1063 32 (634) 6 (429
Figure 1. Forest Plot and Pooled Odds Ratio for Sudden Death/Aborted Su
Forest plot and pooled odds ratio for sudden death/aborted sudden death with
CI  conﬁdence interval.ustained VT or VF should be construed as clinically significant
ndpoints and be grouped with SCD/aborted SCD. If one were to
epeat the analysis using these numbers, LGE on CMR would be
ignificantly associated with SCD/aborted SCD with an odds ratio
f 2.75 (95% confidence interval: 1.10 to 6.84; p  0.02) as shown
n Figure 1. Second, despite not finding significant heterogeneity,
he authors should have tested the robustness of their analysis by
sing alternative weighting methods and random effects model.
tatistical tests for heterogeneity are known to have low power
hen the number of studies is small and weighting methods are
mpacted by low/zero event rates, as is the case with the current
tudy (3). In our analysis using the above proposed event rates for
he O’Hanlon study (2), there was no change in the directionality
r magnitude of the result whether we used random effects model
r fixed effects model with Mantel-Haenszel weighting or Peto
ethod of weighting. The odds ratios were 2.75, 3.37, and 2.76,
espectively with all p values being statistically significant at 0.05.
he consistency of the findings, therefore, add strength to our
onclusion that LGE on CMR predicts clinically significant ven-
ricular arrhythmias (SCD/aborted, SCD/sustained, VT/VF).
Third, though the authors highlight the limitations of the
urrent techniques of LGE ascertainment, and emphasize the need
or more quantitative assessment of LGE, the issue of disparate
GE cutoffs warrants further discussion. While Maron et al. (4)
sed a threshold signal intensity of 6 standard deviations (SD)
bove mean to define LGE, Bruder et al. (5) used a cutoff of 2 SD,
nd O’Hanlon et al. (2) used the “full width half maximum”
ethod, highlighting the wide variability in current methods. To
dd to the uncertainty about the cutoffs for defining LGE in
atients with hypertrophic cardiomyopathy, a recent report by
ppelbaum et al. (6) suggested that intermediate signal intensity
Odds Ratio
 Forest Plot
0.125 0.5 2 8 32 128
Measure (CI)
3.13 (0.67; 14.68)
5.14 (0.65; 41)
13.62 (0.78; 237.55)
1.1 (0.24; 5.03)
2.75 (1.11; 6.84)
n Death
e gadolinum enhancement using revised event rates in the O’Hanlon study (2).is
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Letters to the Editor762LGE (4 but 6 SD) is a better predictor of ventricular tachyar-
hythmias than high signal intensity LGE (6 SD). In conclusion,
s Green et al. (1) appropriately point out, the more important
uestion is not whether LGE predicts SCD, but rather does it
dd incremental information above and beyond that provided by
he conventional and less expensive models based on clinical and
chocardiographic factors. Would we be able to identify patients
ith 2 or more conventional risk factors that would not need
CD based on CMR and would we be able to correctly predict
he need for ICD in a subset of patients with no conventional
isk factors?
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We thank Dr. Alla and colleagues for their insightful comments.
While we agree that sustained ventricular tachycardia (VT)/
ventricular fibrillation (VF) is an important arrhythmic endpoint,
and is certainly a marker for increased risk of sudden cardiac death
(SCD), our goal was specifically to evaluate hard endpoint of SCD
and aborted SCD. As 3 of 4 included studies did not uniformly
report on the incidence of sustained/nonsustained VT/VF, true
prevalence of these events could not be adequately assessed from
these studies. Furthermore, additional studies which do not assess
SCD have demonstrated an association between cardiac magnetic
resonance (CMR) and VT and would need to be included for an
adequate analysis. As proposed, a future multicenter study would
enable more uniform assessment of these arrhythmic events and
other endpoints in the context of traditional risk markers, genetics, and other CMR markers without the statistical limitations inherent
n the current limited data.
Given the assessment of heterogeneity, a fixed effects model was
tatistically justifiable; however, the point made by Alla et al.
egarding the assessment of heterogeneity with a small number of
tudies is well taken. The pooled raw data was reanalyzed assuming
random effects model with very similar results (Table 1). Only
ardiovascular death failed to reach statistical significance (p  0.1)
ith a random effects model. This discrepancy is likely driven by
he low numbers and the discordant results of the Maron study (1),
hich had a younger population as compared with the other 3
tudies (2–4).
Alla et al. raise an interesting point with regard to the current
ethods for quantifying left gadolinium enhancement (LGE) on
he basis of a fixed standard deviation of signal intensity relative to
he remote myocardium, which is dependent upon a number of
onfounding factors including the signal-to-noise ratio of the
mages, gadolinium dose, timing of imaging after contrast admin-
stration, noise statistics, and the assumption that the remote
yocardium is “normal,” which is now suspect given evidence for
iffusely abnormal T1 values (indicating diffuse fibrosis) even in the
bsence of focal fibrosis. This more diffuse fibrosis may also be a risk
or arrhythmic events. Further standardization in the definition of
bnormal LGE in hypertrophic cardiomyopathy would enable us to
etermine if cutoffs based upon SD are truly predictive.
The question about whether LGE adds incremental information
o conventional risk factors cannot be answered with the currently
vailable data. The studies performed to date possess an older
opulation of whom the vast majority have 2 traditional risk
actors for SCD (as their eligibility for CMR in these studies
ignified that they had not already received implantable
ardioverter-defibrillator [ICD] placement for primary prevention
s indicated for those with 2 traditional risk factors). Alla et al.
ropose 2 distinct clinical scenarios in which thoughtful clinical
valuation by the cardiologist is vital: no scar by CMR with 2
raditional risk factors versus scar by CMR with 2 traditional risk
actors. In the first scenario, one must acknowledge the risks
Table 1. Adverse Cardiovascular Events: Fixed Effect Versus
Random Effects Model
Adverse Cardiovascular
Event(s) Model Odds Ratio p Value
Cardiac death Fixed 2.92 (1.01–8.42) 0.047
Random 3.28 (0.79–13.71) 0.104
SCD/aborted SCD Fixed 2.39 (0.87–6.58) 0.091
Random 2.40 (0.87–6.60) 0.091
SCD Fixed 1.45 (0.47–4.52) 0.519
Random 1.51 (0.43–5.32) 0.525
HF death Fixed 5.68 (1.04–31.07) 0.045
Random 5.68 (1.04–31.07) 0.045
All cause mortality Fixed 4.46 (1.53–13.01) 0.006
Random 4.46 (1.53–13.01) 0.006
Values are odds ratio (95% conﬁdence interval).
HF  heart failure; SCD  sudden cardiac death.ssociated with ICD placement and recognize the effects of both
